Shares of Provention Bio soared Monday after the biopharmaceutical company agreed to be acquired by France’s Sanofi (SNY) for $25 a share, or about $2.9 billion. Provention Bio (ticker: PRVB), which f...
Tag: Biopharmaceuticals
First Republic, Provention Bio, Roku, Illumina, Boeing, and More Market Movers
This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit http://www.djreprints.com. https://www.barro...
This is what Warren Buffett, a self-described ‘so-so investor,’ says is his ‘secret sauce’
Stocks are rebounding on the heels of a rotten week — the worst since December for the S&P 500 SPX, +1.15% and the Nasdaq Composite COMP, +1.39%. And as Wall Street analysts go dark, with talk of ...
Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done
An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...
CureVac Stock Just Got Upgraded. It’s Now a Competitor in mRNA Vaccines.
CureVac is ready to compete in the big leagues with its vaccines, according to a UBS analyst who says the soaring stock has more room to rise. UBS analyst Eliana Merle upgraded the shares (ticker: CVA...
European drugmakers including AstraZeneca pony up for U.S.-listed biopharmas
European drugmakers on Monday announced a trio of deals around a billion dollars each to buy U.S.-listed biopharmas at hefty premiums. Anglo-Swedish AstraZeneca AZN, +1.42% AZN, -1.26% said it’s pay...
It’s Pharma Time: Why Merck and Lilly Stock Are Buys, but not Pfizer.
My 2023 biotech outlook calls for continued momentum in name changes. I just need to figure out what the stocks will do. Last year, Respira Technologies became Qnovia. It’s run by a former tobacco exe...
AbbVie cuts earnings forecast due to milestone payments
AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone p...
BioNTech upgraded to buy on high hopes for combined flu/COVID vaccine and oncology pipeline
Bank of America analysts upgraded BioNTech SE stock to buy from hold on Thursday, citing excitement about its mRNA technology and the outlook for a combined flu/COVID vaccine and oncology vaccines tha...
Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis
Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer therapy under development...
Novozymes and Chr. Hansen agree deal to merge
Danish biotechnology companies Novozymes AS NZYM.B, -13.67% and Chr. Hansen Holding AS CHR, +23.64% said Monday they have agreed to merge, creating a biological solutions provider with combined annual...
Twist Bioscience Revenue Growing From $2 To $200 Million As It Eyes The $186 Billion Antibody Market
Emily Leproust, Patrick Finn, Aaron Sato, and Tracey Mullen of Twist Bioscience. Twist Bioscience It’s another beautiful sunny day in San Francisco, and Twist Bioscience (NASDAQNDAQ : TWST) is making ...
AbbVie Stock Slips as Sales Miss Expectations And Bigger Challenges Await.
Stock in AbbVie slipped after the drug company reported a higher profit than expected, while sales fell short. The revenue shortfall may have reminded investors of a challenge AbbVie (ticker: ABBV) fa...
What Stocks Are Moving Monday? Tesla, Palantir, First Solar and More.
Text size Tesla shares rise early Monday. (Photo by Justin Sullivan/Getty Images) Stock futures were trading higher Monday with investors assessing how aggressive the Federal Reserve will be in its ef...
Disney, Coinbase, BioNTech, Rivian, and Other Stocks to Watch This Week
Text size Second-quarter earnings season continues this week, while a pair of July inflation figures and consumer sentiment surveys will be the highlights on the economic-data calendar. On Monday, Tys...
Disney, Coinbase, BioNTech, Rivian, and Other Stocks for Investors to Watch This Week
Text size Second-quarter earnings season continues this week, while a pair of July inflation figures and consumer sentiment surveys will be the highlights on the economic-data calendar. On Monday, Tys...
Pfizer in Advanced Talks to Buy Global Blood Therapeutics for About $5 Billion
Pfizer is in advanced talks to buy Global Blood Therapeutics the maker of a recently approved drug for sickle-cell disease, for about $5 billion, in the latest move by the drug giant to bolster its po...
AbbVie Stock Slips After Earnings, Charge for Potential Opioid Deal
Text size AbbVie said it continues to expect adjusted diluted earnings of between $13.78 and $13.98 per share for the full fiscal year. Dreamstime The drugmaker AbbVie turned in quarterly earnings tha...
This strategist warned investors not to chase momentum at the top. Now he says it’s time to be a contrarian.
Michael Darda, chief economist and market strategist at MKM Partners, was no fan of the stock market when it was registering record highs. “Blinded by liquidity and false expectations of the proverbia...
Merck Is in Advanced Talks to Buy Seagen for Roughly $40 Billion or More
Merck & Co. is in advanced talks to acquire Seagen and is aiming to agree on a purchase of the cancer biotech in the next few weeks, according to people familiar with the matter, in a deal that co...
Opinion: The stock market is telling you loud and clear: Now is not the time to fight the Fed or stand up to the bears.
The S&P 500 Index SPX, -1.85% hit resistance this week when an oversold rally failed near the 4080 level. This continues to support the idea that the index’s rise above 4100 in early February was ...